Provider barriers in uptake of biosimilars: case study on filgrastim
Am J Manag Care. 2023 May 1;29(5):e155-e158. doi: 10.37765/ajmc.2023.89363.ABSTRACTIn this article, we used administrative claims data from the OptumLabs Data Warehouse and American Hospital Association Annual Survey data to examine associations between hospital characteristics and uptake of biosimilar granulocyte colony-stimulating factor treatments. We found that 340B-participating hospitals and non-rural referral center (RRC) hospitals that reported owning rural health clinics were less likely to administer the lower-cost biosimilars, whereas the opposite was true for hospitals that are RRCs. To our knowledge, our study...
Source: The American Journal of Managed Care - May 25, 2023 Category: Health Management Authors: Jessica Chang Pinar Karaca-Mandic Ronald S Go Stephen Schondelmeyer Daniel Weisdorf Molly Moore Jeffery Source Type: research
Provider barriers in uptake of biosimilars: case study on filgrastim
Am J Manag Care. 2023 May 1;29(5):e155-e158. doi: 10.37765/ajmc.2023.89363.ABSTRACTIn this article, we used administrative claims data from the OptumLabs Data Warehouse and American Hospital Association Annual Survey data to examine associations between hospital characteristics and uptake of biosimilar granulocyte colony-stimulating factor treatments. We found that 340B-participating hospitals and non-rural referral center (RRC) hospitals that reported owning rural health clinics were less likely to administer the lower-cost biosimilars, whereas the opposite was true for hospitals that are RRCs. To our knowledge, our study...
Source: The American Journal of Managed Care - May 25, 2023 Category: Health Management Authors: Jessica Chang Pinar Karaca-Mandic Ronald S Go Stephen Schondelmeyer Daniel Weisdorf Molly Moore Jeffery Source Type: research
Provider barriers in uptake of biosimilars: case study on filgrastim
Am J Manag Care. 2023 May 1;29(5):e155-e158. doi: 10.37765/ajmc.2023.89363.ABSTRACTIn this article, we used administrative claims data from the OptumLabs Data Warehouse and American Hospital Association Annual Survey data to examine associations between hospital characteristics and uptake of biosimilar granulocyte colony-stimulating factor treatments. We found that 340B-participating hospitals and non-rural referral center (RRC) hospitals that reported owning rural health clinics were less likely to administer the lower-cost biosimilars, whereas the opposite was true for hospitals that are RRCs. To our knowledge, our study...
Source: The American Journal of Managed Care - May 25, 2023 Category: Health Management Authors: Jessica Chang Pinar Karaca-Mandic Ronald S Go Stephen Schondelmeyer Daniel Weisdorf Molly Moore Jeffery Source Type: research
Provider barriers in uptake of biosimilars: case study on filgrastim
Am J Manag Care. 2023 May 1;29(5):e155-e158. doi: 10.37765/ajmc.2023.89363.ABSTRACTIn this article, we used administrative claims data from the OptumLabs Data Warehouse and American Hospital Association Annual Survey data to examine associations between hospital characteristics and uptake of biosimilar granulocyte colony-stimulating factor treatments. We found that 340B-participating hospitals and non-rural referral center (RRC) hospitals that reported owning rural health clinics were less likely to administer the lower-cost biosimilars, whereas the opposite was true for hospitals that are RRCs. To our knowledge, our study...
Source: The American Journal of Managed Care - May 25, 2023 Category: Health Management Authors: Jessica Chang Pinar Karaca-Mandic Ronald S Go Stephen Schondelmeyer Daniel Weisdorf Molly Moore Jeffery Source Type: research
Provider barriers in uptake of biosimilars: case study on filgrastim
Am J Manag Care. 2023 May 1;29(5):e155-e158. doi: 10.37765/ajmc.2023.89363.ABSTRACTIn this article, we used administrative claims data from the OptumLabs Data Warehouse and American Hospital Association Annual Survey data to examine associations between hospital characteristics and uptake of biosimilar granulocyte colony-stimulating factor treatments. We found that 340B-participating hospitals and non-rural referral center (RRC) hospitals that reported owning rural health clinics were less likely to administer the lower-cost biosimilars, whereas the opposite was true for hospitals that are RRCs. To our knowledge, our study...
Source: The American Journal of Managed Care - May 25, 2023 Category: Health Management Authors: Jessica Chang Pinar Karaca-Mandic Ronald S Go Stephen Schondelmeyer Daniel Weisdorf Molly Moore Jeffery Source Type: research
Apoptosis in Alzheimer ’s disease: insight into the signaling pathways and therapeutic avenues
This study sheds light on apoptotic pathways that are cardinal for neuronal survival and perform crucial role in the occurrence of AD along with the trends in therapeutics targeting apoptosis induced AD. To develop prospective treatments for AD, it is desirable to elucidate potential targets including restoration apoptotic balance, regulation of caspases, Bcl-2 and other crucial protein s involved in apoptosis mediated AD. (Source: Apoptosis)
Source: Apoptosis - April 26, 2023 Category: Molecular Biology Source Type: research
As-Required Filgrastim for Late-Onset Neutropenia Complicating Long-Term Clozapine Treatment: a Case Report
We describe the first case in Hong Kong involving the use of filgrastim, a recombinant form of human granulocyte colony-stimulating factor, to enable clozapine continuation therapy for a severely ill patient with treatment-resistant schizoaffective disorder who developed recurrent neutropenia after almost 20 years of continuous clozapine therapy. Therefore, clinical vigilance is important, regardless of clozapine treatment duration. Filgrastim can facilitate long-term clozapine therapy in patients with clozapine-induced neutropenia.PMID:36991553 | DOI:10.12809/eaap2233 (Source: East Asian Archives of Psychiatry)
Source: East Asian Archives of Psychiatry - March 30, 2023 Category: Psychiatry Authors: K S W Chan N B W Lai M M C Wong P F Pang Source Type: research
